The present invention relates to novel solid forms γ, β, α, δ, ε and ζ of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one of formula I, known as ibrutinib, and processes for preparing the same. The process for preparing consists in dissolution of ibrutinib free base in a solvent at a temperature from 30°C to the melting point of the respective solvent, crystallization of the solution and isolation of the solid fraction.
